People: Interleukin Genetics Inc (ILIU.PK)

ILIU.PK on OTC Markets Group

0.25USD
22 Aug 2014
Price Change (% chg)

$0.02 (+8.70%)
Prev Close
$0.23
Open
$0.24
Day's High
$0.25
Day's Low
$0.21
Volume
18,000
Avg. Vol
8,916
52-wk High
$0.44
52-wk Low
$0.20

Search Stocks

Summary

Name Age Since Current Position

James Weaver

49 2014 Independent Chairman of the Board

Kenneth Kornman

67 2012 President, Chief Executive Officer, Chief Scientific Officer, Director

Eliot Lurier

56 2008 Chief Financial Officer, Treasurer

Scott Snyder

53 2013 Chief Marketing Officer

Joseph Landstra

36 2014 Director

Lionel Carnot

46 2013 Independent Director

Roger Colman

60 2011 Independent Director

William Mills

58 2010 Independent Director

Dayton Misfeldt

40 2013 Independent Director

Biographies

Name Description

James Weaver

Mr. James M. Weaver has been re-appointed as Independent Chairman of the Board of the Company, effective March 31, 2014. He joined the Board of Directors in July 2007 and was appointed Chairman of the Board in September 2007. He is Vice President of Alticor Corporate Enterprises, a member of the Alticor Inc., which is engaged in the principal business of offering products, business opportunities, and manufacturing and logistics services in more than 80 countries and territories worldwide. In this role, Mr. Weaver is responsible for managing the current portfolio of Alticor’s companies and directs its acquisition and growth. Prior to joining Alticor, Mr. Weaver worked for X-Rite Inc. where he held various leadership positions, including Senior Vice President and General Manager, Vice President of marketing and software development, Vice President of marketing and product development, as well as lead executive on several acquisitions. Mr. Weaver also founded and held the position of President and Chief Executive Officer of Bold Furniture Inc, and has held various leadership positions at Steelcase Inc. and Bissell Inc. Mr. Weaver received a Bachelor’s degree in general studies from the University of Michigan in Ann Arbor and serves on several non-profit and private company boards.

Kenneth Kornman

Dr. Kenneth S. Kornman, DDS, Ph.D., is President, Chief Executive Officer, Chief Scientific Officer, Director of Interleukin Genetics, Inc. He has been appointed as the Chief Executive Officer and Director of the company effective August 23, 2012. He was a member of Board of Directors from August 2006 through April 2010. Prior to founding the Company in 1986, Dr. Kornman was a Department Chairman and Professor at The University of Texas Health Center at San Antonio. He has also been a consultant and scientific researcher for many oral care and pharmaceutical companies. Dr. Kornman currently holds an academic appointment at Harvard University. He holds multiple patents in the pharmaceutical area, has published three books and more than 100 scientific papers and has lectured and consulted worldwide on the transfer of technology to clinical practice. Dr. Kornman also holds an MS (Periodontics) and Ph.D. (Microbiology-Immunology) from the University of Michigan.

Eliot Lurier

Mr. Eliot M. Lurier, CPA is no longer Chief Financial Officer and Treasurer of Interleukin Genetics, Inc., effective September 5, 2014. He became Treasurer in July 2008.Prior to joining the Company and since April 2005, Mr. Lurier was Vice President, Finance and Administration and Chief Financial Officer of Nucryst Pharmaceuticals, where he assisted in its initial public offering and was responsible for the company’s reporting to the Securities and Exchange Commission and the implementation of Sarbanes-Oxley requirements. From April 2004 to March 2005, Mr. Lurier served as Chief Financial Officer and Chief Operating Officer for Bridge Pharmaceuticals, Inc., where he established financial policies for managing business operations. From 1983 to 2004, Mr. Lurier held a number of senior-level financial positions, including Chief Financial Officer of Admetric Biochem, Inc., and Chief Financial Officer, Treasurer and Vice President of Finance of Ascent Pediatrics, Inc. From 1981 to 1983, Mr. Lurier was an auditor at Coopers and Lybrand in Boston, MA. He earned a B.S. in Accounting from Syracuse University in 1980 and is a Certified Public Accounting in Massachusetts.

Scott Snyder

Mr. Scott Snyder is Chief Marketing Officer of Interleukin Genetics, Inc. Mr. Snyder joined Interleukin Genetics, Inc . as Chief Marketing Officer in January 2013. Mr. Snyder brings nearly 25 years of marketing and operational management experience in life sciences and consumer healthcare. Most recently, from 2009 to 2012, Mr. Snyder served as Vice President and General Manager at Bausch & Lomb, where he guided the private, equity-led turnaround of the company's flagship contact lens care business. Previously, he spent 20 years at Johnson & Johnson (J&J) in a career spanning all of J&J's business sectors including pharmaceuticals, medical devices and consumer products. While at J&J, Mr. Snyder helped lead the post-acquisition integration of dental products company Orapharma, Inc. and reshaped the company's commercial model. Early in his career at J&J, Mr. Snyder was selected for an expatriate assignment in Europe and has held multiple global roles throughout his career. He served as a U.S. Navy Officer, holds a B.S. Degree in Communications from Northwestern University, and received an MBA from the Kellogg School of Management.

Joseph Landstra

Mr. Joseph M. Landstra is Director of the Company. Mr. Landstra is Director of Finance at Alticor Corporate Enterprises, an affiliate of Pyxis, and was elected as the representative of Pyxis under the terms of the Purchase Agreement (as amended).

Lionel Carnot

Mr. Lionel Carnot is Independent Director of Interleukin Genetics, Inc. Mr. Carnot was a Principal at Oracle Partners, a healthcare hedge fund. He also held several positions in the pharmaceutical industry, including Product Manager for Prozac at Eli Lilly as well as several sales and marketing positions at Rhone-Poulenc Rohrer (now Sanofi). Mr. Carnot was also a strategy and management consultant to the biopharmaceutical industry while at Booz Allen & Hamilton and Accenture Strategic Services. Mr. Carnot is a member of the Board of Directors of Merus B.V., Madrigal Pharmaceuticals and Tallikut Pharmaceuticals, and is a former member of the board of Reliant Pharmaceuticals, Pathway Diagnostics, BioSeek and Nexus Dx. Mr. Carnot holds an MBA with Distinction from INSEAD and an MS with honors in Molecular Biology from the University of Geneva.

Roger Colman

Mr. Roger C. Colman is Independent Director of Interleukin Genetics, Inc. Mr. Colman is Vice President of Corporate Development for Alticor Corporate Enterprises a member of the Alticor of companies. He joined Alticor in 1994 from Readi-Bake, Inc., where he held positions as an operations and distribution executive. Mr. Colman earned a Bachelor of Science degree and a Master’s of Business Administration degree from Grand Valley State University in Allendale, Michigan.

William Mills

Mr. William C. Mills, III, is Independent Director of Interleukin Genetics, Inc. He is currently an independent venture capitalist with over 30 years of experience in venture capital. From 2004 until 2009, Mr. Mills was a managing member of a management company conceived by EGS Healthcare Capital Partners to manage EGS Private Healthcare Partnership III. Earlier, Mr. Mills was a Partner in the Boston office of Advent International, a private equity and venture capital firm, for five years. At Advent, he was co-responsible for healthcare venture capital investments and focused on investments in the medical technology and biopharmaceutical sectors. Before joining Advent, Mr. Mills spent more than 11 years with the Venture Capital Fund of New England where he was a General Partner. Prior to that, he spent seven years at PaineWebber Ventures/Ampersand Ventures as Managing General Partner. Currently, he is a member of the Board of Managers of Ascension Health Ventures. Mr. Mills received his A.B. in Chemistry, cum laude, from Princeton University, his S.M. in Chemistry from the Massachusetts Institute of Technology and his M.S. in Management from MIT’s Sloan School of Management.

Dayton Misfeldt

Basic Compensation

Name Fiscal Year Total

James Weaver

--

Kenneth Kornman

1,218,070

Eliot Lurier

538,964

Scott Snyder

605,592

Joseph Landstra

--

Lionel Carnot

--

Roger Colman

--

William Mills

--

Dayton Misfeldt

--
As Of 30 Dec 2013

Options Compensation

Search Stocks